Toripalimab plus chemo for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether adding the immunotherapy toripalimab to standard chemotherapy improves outcomes for people with locally advanced nasopharyngeal cancer that has not spread to other parts of the body. It compares toripalimab to a placebo while everyone receives chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a type of nasopharyngeal cancer called non-keratinizing carcinoma (WHO type II or III).
- Your cancer is locally advanced (stage T any N2-3 or T4N1) and has not spread to distant organs.
- You are in good general health (ECOG score 0 or 1).
- Your blood counts and liver/kidney function are adequate.
- You have not had prior radiation or chemotherapy for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (toripalimab), chemotherapy, radiation, and omega-3 supplements for people with locally advanced nasopharyngeal cancer that hasn't spread. The goal is to see if this approach works better than standard treatment.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial tests a chemotherapy combination (TC) given after surgery for nasopharyngeal cancer that has come back locally. The goal is to see if this treatment helps prevent the cancer from returning again.
This trial tests adding toripalimab (an immunotherapy) to two different platinum-based chemotherapy regimens as initial treatment for locally advanced nasopharyngeal carcinoma. The goal is to see if this combination is more effective than standard treatment.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people whose nasopharyngeal cancer has come back or spread. It is for those who haven't yet received other treatments for this advanced stage.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.